Category Archives: Data Science
Mars taps former Johnson & Johnson executive to lead new pet care division – Pet Food Processing
BRUSSELS, BELGUIM On July 14, Mars Petcare appointed Nefertiti Greene to president of the companys new division: Science & Diagnostics. Beginning July 18, Greene will direct the new division, expanding its business into pet diagnostics and science, as well as supporting its Waltham Petcare Science Institute.
The new Science & Diagnostics division will work across multiple areas of pet care, including data science, dog and cat microbiomes, health and disease biomarkers and pet nutrition to develop advanced health and wellness care products. The new division builds upon Mars Petcares pet biobank, which launched in June 2022.
Nefertiti will play an integral role in the continued growth of our diagnostics business and accelerate the impact of our science, said Loic Moutault, president of Mars Petcare Global. Were very proud of our diagnostics business, which has a central role in the broader Mars Petcare ecosystem as an important way we deliver on our Purpose. And we recognize that shifting from curative to preventative veterinary care depends on being able to accurately predict and diagnose disease in pets.
Prior to Mars Petcare, Greene served as head of enterprise strategy and chief of staff at business giant Johnson & Johnson. She has also served as US president and global president for Ethicon, Inc., president of Janssen Therapeutics, and US division head for diabetes at Bayer. Greene began her career at Regeneron, focusing on scientific research, marketing and commercial operations.
Greene has nearly 30 years of experience in general management, commercial operations and clinical research in the pharmaceutical and medical technology industries.
Along with an extensive career, Greene has served as an executive advisor for the Enterprise Veterans Leadership Council, a member of the North American Diversity, Equity and Inclusion board, and is currently a member of the Executive Leadership Council. She has also been recognized by the National Association of Female Executives (NAFE) as P&L Leader of the Year.
I am excited to join the Mars Petcare leadership team and look forward to using my experience in the healthcare industry to help build on the successes in diagnostics and science at Mars Petcare, Greene said. As a pet owner Im looking forward to helping further the reach and impact of diagnostics and science for pets around the world.
Read more aboutpersonnel changes throughout the industry.
View original post here:
Mars taps former Johnson & Johnson executive to lead new pet care division - Pet Food Processing
Pros on the Move – July 2022 – CPAPracticeAdvisor.com
Pros on the Move is a round-up of recent promotions and hires in the accounting and tax space.
Withum Names Sixteen New Partners
Withum, a national advisory, technology and accounting firm, has announced its 2022 new partner class. Sixteen team members advance to partner in Withum offices nationwide and join the dynamic, diverse corporate leadership team at Withum, totaling 200 partners. New partners include:
Armanino Welcomes New Partner Matt Baldwin to Denver Office, Expands Real Estate Footprint in the Mile High City
Armanino LLP, one of the 20 largest accounting and business consulting firms in the U.S., today announced it welcomed tax partner Matt Baldwin effective immediately and expanded its office lease in Denver, more than doubling in size. The moves respond to the firms rapid growth in the Mile High City region, as staff has jumped from about a dozen in 2019 to nearly 100 today.
Baldwin joins the firm after stints at EKS&H and most recently at CliftonLarsonAllen. Having served clients in public accounting since 2009, he specializes in corporate and private equity tax. He also brings extensive experience in transactional tax issues, M&A transactions and ASC 740 income tax provisions. Baldwin is a Colorado CPA and member of the American Institute of Certified Public Accountants. He received his bachelors and masters degrees in accounting from New Mexico State University.
Hogan Lovells continues to grow Corporate & Finance capabilities in New York with tax lawyer Jessica Millett
Global law firm Hogan Lovells recently announced the arrival of tax lawyer Jessica Millett as a partner in the firms Corporate & Finance practice group in New York. She is the sixth Corporate & Finance partner to join Hogan Lovells New York office this year. Millett joins from Duval & Stachenfeld, a boutique law firm, where she served as chair of that firms tax practice.
Millett focuses her practice on U.S. tax issues that arise in complex real estate transactions, notably real estate private equity investments, Qualified Opportunity Fund structures, and cross-border investments. She regularly advises clients on tax structuring and documentation for real estate acquisitions, joint ventures, restructurings and refinancing arrangements, including inbound and outbound investments, and structures involving REITs.
Her practice also includes representing sponsors and managers of, and institutional investors in, private investment funds including real estate, distressed debt, and hedge funds, and advising on tax-efficient structures for cross-border securities offerings (debt and equity) and private equity transactions. Millett has experience advising financial institutions on a variety of tax and compliance issues including U.S. withholding and information reporting rules, and tax treaty planning and is currently the chair of the Subcommittee for Foreign Investors of the ABA Tax Section Real Estate Committee.
Millett earned her law degree from Duke University School of Law and her B.A. from Johns Hopkins. Following graduation from Johns Hopkins, she spent two years in the Peace Corps as an education volunteer in Burkina Faso, West Africa.
LBMC Names Five New Shareholders; Growth and Strategic Initiatives Lead to Promotions within Firms Primary Service Lines
LBMC, a top 40 advisory and business consulting firm in the nation, is proud to announce the addition of five shareholders to align with the firms continued focus on serving clients in the advisory, cyber risk, data insights, healthcare and high net wealth space. The new shareholders are comprised of four team members promoted within LBMC and one new to the LBMC family.
Organic Valley Announces Food and Beverage Executive as New Chief Financial Officer
Organic Valley, the countrys leading farmer-owned cooperative of small organic family farms, recently announced that Stephen Famolaro would be joining the cooperative as its new Chief Financial Officer. Famolaro is a Certified Public Accountant and a Certified Management Accountant with more than 30 years financial experience. He holds a certificate in Production and Inventory Management.
Famolaros past roles include CFO of Naked Juice and Century Snacks. He also brings experience in dairy from his time at Dean Foods.
Organic Valley CEO Bob Kirchoff said the cooperative, which is also one of the worlds largest organic consumer brands, will benefit from Famolaros strategy and insight into its financial planning process.
See the original post:
Recommendations for achieving interoperable and shareable medical data in the USA | Communications Medicine – Nature.com
Lack of ascertainment of unique patients
Although HIPAA initially required the creation of a health identifier in 199622, federal funds for unique universal patient identifiers have been banned since Congress prohibited their use due to privacy concerns23. Our failure to implement national, unique identifiers in the USA linking a patients data to their healthcare professionals and HIS systems leads to unlinked, incomplete, and often duplicated records, and is another significant source of data quality problems that have been avoided incountries that have implementeunique identifiers23. In addition, it is still nearly impossible for a person to access their own vaccination records if they are in databases separate from their EHR records or were submitted by paper or fax. It is also difficult or impossible to carry out the early cancer prevention studies24 that require that complete clinical information be linked to the correct patients even when they change health providers.
Although the prospect of unique patient identifiers raises valid privacy concerns, it can be argued that it would be easier to monitor and protect privacy with a single, properly encoded universal identifier than with a multitude of poorly documented ones. The absence of a unique identifier is actually one of the greatest causes of invasion of privacy, because typically over half of the EHRs in an institution will mistakenly include someone elses data [Personal communication by Dr. W. Ed Hammond] that may be identifiable.
The current reliance on data aggregation techniques to protect patient privacy significantly delays our access to the information and impedes our understanding of the trajectory of diseases in individual patients, with potentially adverse consequences for their medical care and for identifying critical patient-level variables for subsequent research studies. We must therefore invest in better and updated privacy protection systems and law enforcement solutions. As data scientists, we are concerned about the limitations of HIPAA for privacy protection, due to the ease that such data can be re-identified. Our laws and regulations need to balance individual privacy protection, with making data available for improving health outcomes. At a minimum, the approach to governance we adopt must ensure the following: the system is able to identify and control who can have the authorized level of access to the medical records; every user has a unique ID and a secure password; audit trails are used to track every user activity, and to provide accountability; only authorized personnel can access audit trails, and assess who has accessed or modified a record; and the data storage provider is not able to access personal identifiable information.
A single patient identifier also has health equity ramifications in its favor. Patients who are poorer typically have less insurance coverage or none at all and often switch healthcare systems. They are underrepresented in HIS and research studies, and less likely to have their specific needs understood. A unique identifier should improve the representation of these patients in our HIS and thus our ability to address health inequities.
The inadequacy of our current system for data collection is well illustrated by our failure to collect data as fundamental as mortality in a standardized fashion. Fatal outcomes are not incorporated into the medical record unless death occurs during hospitalization. When needed for public health measures, epidemiological studies, and other research, data on death may be obtained from private services that collect information from funeral homes and obituaries, disease registries unconnected to EHRs, or from the National Death Index website. This website is typically late in gathering mortality information as it is collected by a multitude of disparate local and state systems before being reported to the National Center for Health Statistics. Comprehensive data on mortality and cause of death should be methodically linked to clinical data for the over 330 million individuals in the USA (as we have begun to do for COVID-19 cases). This information will allow for the creation of focused decision support systems for clinical data that are better designed to prevent serious and fatal medical errors, one of the top causes of death in hospitals in the USA25.
Clinical laboratories began collecting digitized data in the 1960s. Although these data support 60 to 70 percent of decisions related to diagnosis, treatment, hospital admission, and discharge, they remain poorly codified, complicated to process, and are underused for medical decision-making and research.
USA programs that defined the minimum government standards for EHRs have offered laboratories incentives to adopt proposed standards for messaging and encoding laboratory data. Unfortunately, serious functional problems still exist with the coding of laboratory test identifiers. There are multiple ways for the same analytes to be represented by different labs and instruments and this results in improper assessments of coded terms and incorrect code selection and categorization. Moreover, coding systems often do not allow for transparent incorporation and transmission of the limits of detection of a test, the presence of interfering substances, and how a particular analyte is measured. Also, failure to enforce the use of consistent quantitative units of measure is a frequent source of data errors.
There is a pressing need for an expanded infrastructure to support the collection and distribution of the stable reference standards needed to support the accurate calibration and safe integration of the results from equivalent tests measuring the same analyte,performed by different instrument platforms or laboratories26,27. The Office of the National Coordinator for Health Information Technology recognizes this problem when it states, Harmonization status indicates calibration equivalencies of tests and is required to verify clinical interoperability of results. Tests that are harmonized may be interpreted and trended together, and may use the same calculations, decision support rules, and machine learning models. Tests that are not harmonized should be interpreted and processed individually, not in aggregate with other tests.3
This infrastructure will simplify the identification of a natural functional interoperability pathway that can be used as a backbone for integrating the currently unwieldy, inconsistent, and incomplete data coding standards for laboratory data. An illustration of the consequences of the failure to fully standardize laboratory data collection and calibration of the results is the limited understanding of the evolving prevalence of COVID-19, due to the inability to account for the performance differences of the over 1,000 SARS-CoV-2 diagnostics that are listed worldwide28. We also need to understand their performance characteristics according to the particular purpose for which a test is being performed (e.g., permission to travel, to access specific facilities, etc.) 29.
The world-wide-web and online business transaction systems such as Amazons e-commerce system were built with a clear understanding of the value of interoperability. These systems ensure that the correct data are collected and stored in an organized, automatically aligned format that is optimized to address new communication requirements and analytical functions. Realizing this scenario for health data will require changes in current practices. Since individual enterprises have built one-of-a-kind systems, there are often strong financial reasons not to share proprietary information. Current laws prohibiting information blocking have not accomplished their purpose, because it is impossible to effectively oversee the thousands of unique versions of HIS.
Given this scenario, it would be useful, once the needed information and data routes are identified and categorized, to develop prototype systems to demonstrate the benefits of profound change in how we manage health information. The development, testing, and validation of these prototypes for addressing the various requirements of patient care and research and development should be based on the integrity, completeness, traceability, and usability of the data; on the avoidance of preventable medical errors; and on measurable improvements in health outcomes.
In contrast to other data transactions for which federal regulations are seeking to increase interoperability (e.g., using ICD-10 coding for billing), in the USA there is no clear business model that incentivizes standardization of laboratory data coding and its integration across medical encounters. Nor is there a single coordinated authority in the USA to monitor and enforce the adoption of, and adherence to, such standards or the transmission of intact laboratory data to end users. Interoperable standards for laboratory data are still very immature (paper and fax lab submissions are still commonplace), and still rely on billing codes for managing and understanding this information, despite their limited scope. For example, there are only 12 Current Procedural Terminology codes used for billing reimbursement that identify the COVID-19 or SARS-COV-2 infectious agent or their antibody response30, while the FDA lists 357 identifiers for COVID-19 testing 31.
Therefore, we suggest that one area that we should use as a model for how to achieve interoperability of patient data, and where favorable incentives for reform may already exist, is in the processing of clinical laboratory data in drug marketing applications submitted to the FDA. Currently, such data undergo multiple transformation steps before regulatory submission, and although results in a given new drug application may be calibrated, the results for many equivalent analytes coming from different sponsors, laboratories, and instruments are not necessarily calibrated the same way3,26,27.
We propose to begin the process of prototype development by creating a centralized calibration process for routine and critical analytes so that results collected during clinical trials will be equivalent regardless of the instrument or the laboratory. The aim is to eliminate the severe problems that result from customized data systems and demonstrate that time-consuming mapping and translation errors, and the associated loss of information, can be avoided while adding traceability and clarity to the clinical laboratory data in marketing applications. The recent phenomenon of increased mergers between central labs supporting pharmaceutical company sponsors and labs that support hospital networks will enable the systematic identification and removal of many deficiencies that derived from multiple sources of lab data, and help implementation of robust and universal data standards. We expect that the time and cost savings and the gains in accuracy demonstrated by a prototype system for clinical laboratory data will be welcomed by the pharmaceutical and device industries, the research and public health communities, and patients. In its processing of lab data, this initiative will include all the standardized data elements needed for analysis of regulatory data submissions, including those related to demographics, diagnosis, medical history, laboratory tests, death, and cause of death. Such standards will greatly enhance regulatory review of marketing applications across multiple sponsors and facilitate comparison of clinical trial lab results across applications, providing valuable feedback to the pharma sponsors.
When it reaches a level of maturity, the prototype for handling laboratory and other clinical data in regulatory submissions could be expanded to non-regulatory contexts, including routine patient care. The lessons learned could eventually be applied to the evaluation and certification of EHRs and decision support systems. The knowledge gained in how to create a truly interoperable system could also be used to address the analytical needs of other data resources including registries, repositories of real-world data, and regional data exchanges.
See the original post here:
Striveworks Spotlighted on the CRN 2022 Emerging Vendors List – PR Newswire
MLOps Platform Chariot Puts Firm on Artificial Intelligence/Machine Learning Tools List
AUSTIN, Texas, July 18, 2022 /PRNewswire/ -- Striveworks announced today thatCRN, a brand ofThe Channel Company, namedthe firmto its 2022 Emerging Vendors list in the AI/Machine Learning Tools category. This annual list recognizes the fast-rising technology vendors that have exhibited a commitment to driving positive change and continuous growth in the IT and technology space by delivering innovative, cutting-edge solutions.
The technology vendors featured on CRN's 2022 Emerging Vendorsall six years old or youngerare bringing a fresh approach to solving the IT challenges facing customers today, enabling their partners to deliver unique solutions.
Striveworks was selected because of its easy-to-use Chariot MLOps platform. The platform powerfully handles the entire MLOps lifecycle, and does so within a low-code/no-code interface that offers multidisciplinary teams a collaborative place to drive outcomes and deploy models rapidly at scale. Users can produce algorithms that might have taken days or weeks to build in a matter of minutes or hours within Chariot.
Striveworks' technologies have been widely used in the public sector since its inception in 2018, with the firm receiving a mention in the National Security Commission on Artificial Intelligence's 2020 Final Report as the exemplar of democratized AI. The Chariot platform was built out of early experiences providing mission-critical data science alongside subject matter experts, and the platform is now the newest tool for Fortune 500 and channel partners looking to make better models, faster.
"We're so happy and humbled for Striveworks to be selected for the CRN Emerging Vendors list," said Jay Tabb, Executive Vice President for Security and Analytics at Striveworks. "We continue to grow our list of highly satisfied customers as we make machine learning and AI more accessible to everyone. We succeed when our customers achieve a decision advantage through leveraging the true power in their data."
"As part of our 2022 Emerging Vendors list, CRN recognizes technology vendors that are transforming the IT channel by providing revolutionary and innovative products that help customers manage ever-evolving IT demands," said Blaine Raddon, CEO of The Channel Company. "As a trusted industry resource, CRN's Emerging Vendors list gives solution providers insight into the latest groundbreaking IT channel technologies.
The CRN 2022 Emerging Vendors list will be featured in the August 2022 issue of CRN Magazine and online atwww.CRN.com/EmergingVendors.
About Striveworks
Striveworks is a pioneer in operational data science for national security and other highly regulated spaces. Striveworks' flagship MLOps platform is Chariot, purpose-built to enable engineers and business professionals to transform their data into actionable insights. Founded in 2018, Striveworks was highlighted as an exemplar in the National Security Commission for AI 2020 Final Report.www.striveworks.com
About The Channel Company
The Channel Company enables breakthrough IT channel performance with our dominant media, engaging events, expert consulting and education, and innovative marketing services and platforms. As the channel catalyst, we connect and empower technology suppliers, solution providers and end users. Backed by nearly 40 years of unequalled channel experience, we draw from our deep knowledge to envision innovative new solutions for ever-evolving challenges in the technology marketplace.www.thechannelcompany.com
Media Contact:Tracy Shank[emailprotected]805-874-2650
SOURCE Striveworks, Inc.
Excerpt from:
Striveworks Spotlighted on the CRN 2022 Emerging Vendors List - PR Newswire
Elon Wants to Fight the Bots – Bloomberg
Programming note:Dont feel bad about my vacation or anything.I am trying to take some time to focus on other work, soMoney Stuff will be published infrequently for the next few weeks. On that note, tomorrow is the Bloomberg Crypto Summit in New York. At 11:25 a.m., I will be moderating a conversation with Sam Bankman-Fried. Every time I talk with SBF it is fun, and last time I diditmight have marked the top for the crypto market? Perhaps tomorrow will mark the bottom.I am looking forward to it.
In some parallel universe, Elon Musks dispute with Twitter Inc. is about how many bots there are on Twitter. In that universe, Twitters merger agreement with Musk contains a representationthat no more than 5% of Twitters monetizable daily active users, or mDAUs, are bots, Musks obligation to close the merger is contingent on this representation being true,and Musk has discovered that it iswrong. Therefore he is able to walk away from the agreement, and maybe even sue Twitter for damages for misleading him.
See the article here:
Media statements – WA Health Hackathon to help drive innovation in healthcare sector – Media Statements
Digitisation and the adoption of data-driven technologies in healthcare can play a key role in helping to improve processes and systems within the sector.
The WA Data Science Innovation Hub (WADSIH) is hosting the WA Health Hackathon (August 8 to 18, 2022) for its second consecutive year with the aim of developing innovative, digital healthcare solutions.
Medical Research Minister Stephen Dawson said the WA Health Hackathon brings together data professionals, digital specialists, innovators and students to work together to discuss and develop ideas to enhance healthcare outcomes.
This year the cohort will be tackling five key areas:
In addition to addressing healthcare challenges, participants will have the opportunity to take part in a series of upskilling workshops to support professionals and students in the innovation space.
For more information about the WA Health Hackathon program and how to register visit: https://wadsih.org.au/wa-health-hackathon
Comments attributed to Medical Research Minister Stephen Dawson:
"It's through collaboration, cooperation and consideration with forums such as the WA Health Hackathon that we can initiate change, develop and implement innovative ideas in health care.
"The McGowan Government is committed to laying the groundwork to establish the State as a global hub for medical research and the development of digital health. Earlier this year we announced an $8.65 million package to progress this vision.
"The WA Health Hackathon plays an integral role in this process and this year's event will build on the great success of last year.
"I encourage those interested to register and participate in this engaging forum and help make a big difference on how we revolutionise health care in the future."
Comments attributed to the WA Data Science Innovation Hub Director Alex Jenkins:
"We've got a fantastic group of organisations supporting this year's event which gives participants a range of exciting training opportunities throughout the week, and of course some amazing prizes for the winning teams.
"The best solutions will be selected by a panel of industry judges who will make their decision based on design principles, innovation, viability, scalability and social impact.
"There is still time to register and I encourage those working in the digital or data space to play a role and have a say in how we shape the future."
Minister's office - 6552 5800
Visit link:
Why investment in the social sciences is critical to public health – The Hill
We got the biological science right, but we didnt get the social science right.
That poignant assessment of the U.S. response to the pandemic by White House Coronavirus Response Coordinator Ashish Kumar Jha at theAspen Ideas Forumcaptured the sharp contrast between the remarkable success in the rapid development of vaccines and the persistent challenges in communicating health information to the American public challenges that ultimately increased suffering.
Carnegie MellonsDelphi Group, which pioneered the use of AI and machine learning to build real-time models of the pandemic, made essentially the same point. As the teams leading scientist, Roni Rosenfeld, has stated, while advances in data science facilitate more accurate tracking of disease outbreaks, we lack the capacity to model human behavior and the impact that lack of trust in government can have on successfully combating a deadly pandemic.
These observations highlight the importance of acting on the recommendations of both the Biden administration and bipartisan leadership in Congress to more effectively integrate the social sciences into efforts to respond effectively to not only pandemics but also the wide range of serious challenges we face as a society, such as climate change and the transition to clean energy it requires, cybersecurity, inflation and crime.
In my view, solutions to these problems require both the humanities and social sciences, but in response to Jhas remarks, I will focus on the latter.
The social sciences are essential to designing strategies that involve science and technology that will be effective in the real world, in part because they are crucial in communicating information about science or technology to the general public. Vaccine hesitancy is a perfect example. Social scientists have learned that different social groups (determined by race, ethnicity, age and religion, not just political party) all had different initial responses to the vaccine, and these groups uptake behavior all evolved differently as a result of national- or community-level communication efforts. One size does not fit all, and understanding human behavior and decision making are key to customizing strategies and building trust.
Another example isthe integration of advances in artificial intelligence into society at large. AI is fueling incredible advances in efficiency and automation, but these advances have the potential to either improve peoples lives or put vast numbers of people out of work or both. We cant stop the technology from being developed, and most of us dont want to, but how AI plays in our society will be determined by how we manage it which we cannot do without understanding the social world the technology will be embedded within.
What Jhas observation and the examples noted above speak to is the urgent need for a national strategy to reinvest in and reinvigorate the social sciences. This strategy should have three key pillars:
Technology is advancing rapidly because industry has a large desire to put technology to use in advancing its goals and government agencies, particularly those focused on national security, are investing heavily in basic technology research. These are both good things, but we need commensurate investment in our ability to understand the society those technologies will become a part of and influence. Many efforts are already underway. The National Science Foundation has integrated social and behavioral science programs and funding with initiatives to accelerate U.S. leadership in the development of critical technologies. We need much, much more.
Richard Scheines is the Bess Family Dean of Carnegie Mellon Universitys Dietrich College of Humanities and Social Sciences and a professor of philosophy.
See the rest here:
Why investment in the social sciences is critical to public health - The Hill
SAP Analytics Experts from Amazon Web Services, IDC, and Pyramid Presenting at SAPinsider 2022, the Premier Independent SAP Technologies Conference -…
LONDON & NEW YORK CITY & TEL AVIV, Israel--(BUSINESS WIRE)--The Chief Technology Officer and Senior Vice President of Strategic Alliances from Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, will deliver main stage presentations with Chandana Gopal, Research Director, Future of Intelligence, IDC and Cristina Martin Greysman, WW Head of SAP on AWS Partner & Alliance Strategy at Amazon Web Services, at SAPinsider 2022, July 19 21 in Las Vegas. Register for SAPinsider 2022 with our discount code: PYRAMIDVIP.
Key Points:
Take Action:
About Pyramid Analytics
Pyramid is whats next in analytics. Our unified decision intelligence platform delivers insights for anyone to make faster, more intelligent decisions. The Pyramid Decision Intelligence Platform provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. The Pyramid Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
More here:
POSTDOCTORAL RESEARCHERS, INSIGHT AND CONFIRM SFI RESEARCH CENTRES, DATA SCIENCE INSTITUTE, COLLEGE job with NATIONAL UNIVERSITY OF IRELAND, GALWAY |…
Applications are invited from suitably qualified candidates for two full-time, fixed-term positions as Postdoctoral Researchers with the Insight and Confirm SFI Research Centres hosted at the Data Science Institute in the National University of Ireland Galway.
The successful candidates will work in the area of the Semantic Web, ontologies, interoperability, data acquisition, data federation, data processing, machine learning, data analytics, and decision making with applied use cases in industry. The candidates will have an opportunity to work closely with our third-level and industry partners to pursue goal-oriented research.
These two positions are funded by Science Foundation Ireland, and are available from the 1st September 2022 for one year.
Job Description:
The successful candidates will be working with a team of around 10 researchers working closely with our third-level and industry partners on a range of topics including data semantics, data interoperability, data processing and acquisition, machine/deep learning, real-time data analytics, and decision support systems ultimately aiming to design and develop cutting-edge technologies, algorithms, and system solutions for industry and society.
Professor John Breslin is a Principal Investigator with the Insight SFI Research Centre for Data Analytics. The Confirm SFI Research Centre for Smart Manufacturing s activities at NUI Galway are also led by Professor John Breslin (Principal Investigator).
Duties:
The successful candidates will:
Qualifications/Skills required:
Essential Requirements:
Desirable Requirements:
Salary: 39,522 to 51,036 per annum.
Start date: Positions are available from 1st October 2022.
Continuing Professional Development/Training:
Researchers at NUI Galway are encouraged to avail of a range of training and development opportunities designed to support their personal career development plans.
Further information on research and working at NUI Galway is available on Research at NUI Galway
For information on moving to Ireland please see http://www.euraxess.ie
Insight is the Science Foundation Ireland (SFI) Research Centre for Data Analytics. It is one of the largest data analytics centres in Europe. It seeks to derive value from Big Data and provides innovative technology solutions for industry and society by enabling better decision-making. It supports 450 researchers across the country in areas such as the Fundamentals of Data Science, Sensing and Actuation, Scaling Algorithms, Model Building, Multi Modal Analysis, Data Engineering and Governance, Decision Making and Trustworthy AI. More information on the Insight SFI Research Centre for Data Analytics is available at http://www.insight-centre.org
Confirm is the Science Foundation Ireland (SFI) Research Centre for Smart Manufacturing. Confirm benefits from expertise across nine core research performing organisations in Ireland and 16 international collaborations. Confirm has 42 industry partners across the MNC and SME sectors including Johnson & Johnson, VMware, and many others. The selected candidate will have a good opportunity to work with academia as well as closely collaborate with industry partners. Further information about the Confirm SFI Research Centre for Smart Manufacturing is available at http://www.confirm.ie.
Galway is located on the beautiful west coast of Ireland, 'between' Europe and the US, making it an ideal hub for national, European and international research. Informal enquiries concerning the post may be made to Professor John Breslin.
To Apply:
Applications to include a covering letter, CV, and the contact details of three referees should be sent, via e-mail (in word or PDF only) to Professor John Breslin, john.breslin@nuigalway.ie
Please put reference number NUIG RES 175-22 in subject line of e-mail application.
Closing date for receipt of applications is 5.00 pm 19th August 2022
Interviews are planned to be held on 26th August 2022
We reserve the right to re-advertise or extend the closing date for this post.
National University of Ireland, Galway is an equal opportunities employer.
All positions are recruited in line with Open, Transparent, Merit (OTM) and Competency based recruitment
NUI Galway provides continuing professional development supports for all researchers seeking to build their own career pathways either within or beyond academia. Researchers are encouraged to engage with our Researcher Development Centre (RDC) upon commencing employment - see http://www.nuigalway.ie/rdc for further information.
Excerpt from:
Winning Scientific Research Announced for Heart Failure and Social/Structural Determinants of Health – Diagnostic and Interventional Cardiology
July 15, 2022 The American Heart Association, the leading voluntary organization devoted to longer, healthier lives, recognizes structural racism as a major cause of poor health and premature death from heart disease and stroke.[1]Areas in the U.S. with more social vulnerabilities have higher premature mortality from cardiovascular disease.[2]The American Heart Association, and the Association of Black Cardiologists hosted a six-month data challenge in which researchers tested the relationships between heart failure and health disparities, social determinants of health and structural determinants of health. The results were evaluated by a peer review group of nearly 30 experts in the field. Four teams of researchers are winners.
Congratulationsto these researchers for their exceptional work in the heart failure data challenge, said Michelle A. Albert, M.D., M.P.H., past president of the Association of Black Cardiologists and president of the American Heart Association. Improving our understanding of how social determinants of health impact certain populations in order to develop consequential targeted solutions requires harmonization of different types of data. These teams must be commended for their efforts at addressing health equity, one of the most pressing areas in healthcare.
Ambarish Pandey, M.D. (University of Texas Southwestern Medical Center, Dallas) led the study Impact of Social and Structural Determinants of Health on Hospital Length of Stay among Heart Failure Patients according to Race,with his team Matthew W. Segar, M.D., M.S. (Texas Heart Institute, Houston), Shreya Rao, M.D., M.P.H. (University of Texas Southwestern Medical Center, Dallas), Sandeep Das, M.D., M.P.H., M.B.A. (University of Texas Southwestern Medical Center, Dallas).
The study leveraged the American Heart AssociationsGet With The Guidelines Heart Failureregistry data to identify key ZIP code level social determinants of health parameters that are significantly associated with prolonged length of stay following heart failure hospitalization.
Gargya Malla, M.D., M.P.H., Ph.D. (University of Alabama at Birmingham) led the projectNeighborhood Disadvantage and Risk of Heart Failure Among Black and White Adults: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.Her team included researchers from University of Alabama at Birmingham; Weill Cornell Medicine, New York; East Carolina University, Greenville, North Carolina, and Drexel University, Philadelphia. The study investigated incident heart failure risk associated with living in disadvantageous neighborhoods and if this association was different for white and Black adults in the US.
Jeffrey Tran, M.D. and Nancy Sweitzer, M.D., Ph.D. (University of Arizona Sarver Heart Center, Tucson, Arizona)led the study The Effect of Socioeconomic Determinants of Health on the Prescription of Angiotensin Receptor Blocker/Neprilysin Inhibitors at Discharge from the Hospital, which investigated how socioeconomic determinants of health impact the odds of being prescribed angiotensin receptor blocker/neprilysin inhibitors in patients experiencing heart failure with reduced ejection fraction being discharged from the hospital. The study leveraged multilevel multiple imputation to handle missing data and use existing data to the fullest extent possible.
Vishal Rao, M.D., M.P.H. (Duke University Medical Center, Durham, North Carolina) and Melissa Caughey, Ph.D. (University of North Carolina Chapel Hill, North Carolina) led the projectIn-Hospital Outcome Differences in Patients Hospitalized for Heart Failure Across Neighborhood Socioeconomic Disadvantage in the American Heart Association Get With The Guidelines - Heart Failure Registry.The team explored the association between socioeconomic status disadvantage and in-hospital heart failure outcomes in patients from diverse neighborhoods in the Get With The Guidelines - Heart Failure Registry.
The research findings from all the winning studies are currently under consideration for publication in peer-reviewed scientific journals and are not yet publicly available.
These types of data challenge projects provide much-needed insights into the relationships between heart failure and social determinants of health. Data challenges bring in top level scientists that provide novel and effective solutions, said Jennifer Hall, Ph.D., chief of data science for the American Heart Association.
Health disparities include environmental threats, individual and behavioral factors, inadequate access to health care, poverty and educational inequalities. Social determinants of health include resources such as food supply, housing, economic and social relationships, education and health care. Structural determinants of health include economic, governing and social policies that affect pay, working conditions, housing and education.
Researchers had access to the American Heart Associations Get With The Guidelines Heart Failure registry data on the American Heart AssociationsPrecision Medicine Platformto conduct their analyses. The Precision Medicine Platform is an easy-to-use research interface that allows researchers to collaborate from anywhere in the world in a secure, cloud-based environment. With artificial intelligence and deep machine learning capabilities, the Precision Medicine Platform gives researchers the power and speed to bring their data together collaboratively and accelerate their findings into impactful discoveries for patients faster than ever before.
For more information:www.heart.org
[1]Churchwell K, Elkind MSV, Benjamin RM, et al. Call to action: structural racism as a fundamental driver of health disparities: a presidential advisory from the American Heart Association.Circulation. 2020;142(24).
[2]Khan SU, Javed Z, Lone AN, et al. Social vulnerability and premature cardiovascular mortality among us counties, 2014 to 2018.Circulation. 2021;144(16):1272-1279.
View original post here: